/

Empresas

An

No verificado

Ankyra Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa

15/12/2025

Mercado laboral

Oncología

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)

Fuente

Ankyra Therapeutics

Editor

1.00

0

17/11/2025

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer

Fuente

Ankyra Therapeutics

Editor

1.00

0

04/11/2025

Ciencia

Veterinaria

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Fuente

Ankyra Therapeutics

Editor

1.00

0

28/04/2025

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab

Fuente

Ankyra Therapeutics

Editor

1.00

0

28/04/2025

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab

Fuente

Ankyra Therapeutics

Editor

1.00

0

05/11/2024

Industria

Oncología

Salud

Medicina - Varios

Medicina nuclear

Farmacéutica

Biotecnología

Ankyra Therapeutics Announces First Visceral Tumor Patient Dosed in Phase 1 ANCHOR Clinical Trial of ANK-101, an Anchored Interleukin-12 (IL-12)

Fuente

Ankyra Therapeutics

Editor

1.00

0

23/09/2024

Mercado laboral

Biotecnología

Farmacéutica

Salud

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Fuente

Ankyra Therapeutics

Editor

1.00

0

04/10/2023

Accesorios de moda

Ir de compras

Gestión empresarial

Medicina - Varios

Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Fuente

Ankyra Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0